Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses, today announced its CSF-1 eye drop has successfully met the primary endpoint in a Phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically significant improvement in distance-corrected near visual acuity of a 3-line or greater gain. In addition, CSF-1 demonstrated an exceptional safety and tolerability profile. Full results from the study will be submitted for presentation at an upcoming medical meeting. “The successful completion of the Phase 2b study is a significant milestone for Orasis. We are encouraged by these results and CSF-1’s potential to improve the quality of life for people with presbyopia,” said Elad Kedar, chief executive officer of Orasis. “CSF-1 can potentially alleviate the burden of reading glasses and offer a meaningful solution for billions of people living with age-related farsightedness worldwide.”
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!